retatrutide trial phase Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal 3 obesity Retatrutide, a TRIPLE agonist (GLP1,
Description
We call it sarcopenia
Men were not randomized to high lycopene versus low lycopene, so the study shows an association, not proof that lycopene itself prevents prostate cancer
95% CI 0.781.17
Exercise counseling and reduced calorie diet 68 weeks
Moreover, patient preference is gaining importance in clinical decision-making
These economic changes are closely tied to evolving dietary patterns
